Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC. [Phase 3]

View source ↗

Summary

A phase 3 trial evaluating the efficacy and safety of the combination of TQ-B211 with docetaxel in HER2-positive metastatic breast cancer is ongoing and status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• TQ-B211

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: HER2-positive Metastatic Breast Cancer | Phase 3 | Status: UNKNOWN